Inexpensive drug protects against COVID-19 inflammation in pre-clinical trials 31 March 2021 | By Victoria Rees (Drug Target Review) A drug called topotecan (TPT) was administered to mice up to four days after COVID-19 infection, reducing inflammation and morbidity.
AI method for generating new proteins could accelerate drug development 31 March 2021 | By Victoria Rees (Drug Target Review) A novel artificial intelligence (AI) technique called ProteinGAN has shown success at studying well known proteins to develop new ones.
Prime editing demonstrates success at precise gene editing in mice 31 March 2021 | By Victoria Rees (Drug Target Review) Researchers have shown that prime editing is able to effectively edit genes in mice but without the off-target effects of CRISPR.
CD8+ T cells recognise recent SARS-CoV-2 variants, scientists say 31 March 2021 | By Victoria Rees (Drug Target Review) Researchers have revealed that T cells in blood samples from people who recovered from COVID-19 responded to SARS-CoV-2 variants.
Scientists develop synthetic cell that grows and divides uniformly 30 March 2021 | By Victoria Rees (Drug Target Review) Researchers have created a single-celled synthetic organism able to grow and divide that could be used to produce drugs and detect disease.
Hydrogel used to revert cancer cells back to cancer stem cells 30 March 2021 | By Victoria Rees (Drug Target Review) A new hydrogel has been shown to convert cancer cells to cancer stem cells within 24 hours, in six different human cancer cell line types.
Novel technique provides detailed map of lung pathology in COVID-19 30 March 2021 | By Victoria Rees (Drug Target Review) Researchers have used imaging mass cytometry to analyse the cellular landscape of diseased lung tissue in severe COVID-19, revealing insights into the disease.
Antibody could be used in tooth regeneration therapy, study shows 30 March 2021 | By Victoria Rees (Drug Target Review) A mAb could be used in tooth regeneration therapy, after a single administration generated new teeth in mice and ferrets.
Platelet-based therapeutic formulation targets tumours in mouse models 29 March 2021 | By Victoria Rees (Drug Target Review) A new delivery vector using platelets has shown success in pre-clinical trials at delivering photothermal particles and immunostimulators to tumours.
Inhibiting IRE1α pathway could be novel therapeutic strategy for lupus 29 March 2021 | By Victoria Rees (Drug Target Review) A study has revealed that blocking a molecule called IRE1α could prevent the release of neutrophil extracellular traps in lupus pathogenesis.
Aptamer inhibits SARS-CoV-2 with novel mechanism of action, study shows 29 March 2021 | By Victoria Rees (Drug Target Review) An aptamer that can bind a different part of SARS-CoV-2 than known inhibitors could enhance treatments against coronavirus mutations.
New drug target identified to potentially fight neuroblastoma 29 March 2021 | By Victoria Rees (Drug Target Review) Researchers have revealed that the protein ALYREF promotes the effects of the neuroblastoma gene, MYCN, making it a target.
Scientists find evidence that SARS-CoV-2 infects cells in mouth 26 March 2021 | By Victoria Rees (Drug Target Review) Researchers have shown that SARS-CoV-2 infects mouth cells, which could inform the development of treatments against the oral symptoms of COVID-19.
Antibodies and remdesivir used to treat Marburg virus in rhesus macaques 26 March 2021 | By Victoria Rees (Drug Target Review) The combination of mAbs and remdesivir induced an 80 percent protection rate against Marburg virus in rhesus macaques, according to a new study.
Novel label-free assay developed to profile immune response to infection 26 March 2021 | By Victoria Rees (Drug Target Review) Researchers have created an immune assay that can profile host immune responses to infection and is faster than current methods.
